logo
Scientists make disturbing discovery in analysis of human bodily fluids: 'Further research is required'

Scientists make disturbing discovery in analysis of human bodily fluids: 'Further research is required'

Yahooa day ago

A new study published in Environmental Research identified microplastics in various body fluids among people suffering from respiratory illnesses.
An Iran-based research team collected urine, mucus, and lung lavage fluid samples from 30 participants who suffered from respiratory illnesses. They found a total of 490 microplastics in the samples, representing an array of colors, sizes, and plastic types.
These tiny plastic particles were most abundant in the mucus; all 30 patients had microplastics in those samples, and 358 total microplastics were found across all mucus samples. Meanwhile, only nine microplastics were detected in urine among eight of the patients. A total of 123 microplastics were identified in the lavage fluid samples, where a higher proportion of larger fibers were also discovered.
The authors said their observations suggest that inhaled and ingested microplastics might be fractionated differently through the body.
"Further research is required to determine why and how particles larger than theoretical limits are present in these fluids, along with their biopersistence and potential acute and chronic health impacts," they added.
Microplastics break off from larger plastics, and they can be found all around us, from the air we breathe to the water we drink and the food we eat. One study found that nearly all tested protein samples, including chicken and tofu, contained microplastics.
These tiny plastic particles have also infiltrated our bodies. One study found significant levels of microplastics in the penises of four out of five men undergoing erectile dysfunction–related surgery, while another discovered that a growing number of microplastics are appearing in our brains.
Research examining the impacts of microplastic exposure is ongoing, but it has so far been tied to cancer, dementia, and impaired blood flow in the brain, among other health concerns.
Removing microplastics from the environment is difficult but not impossible. One group of scientists discovered a way to filter them out of water using egg whites, and another team found a way to remove up to 99.9% of pollutants — including microplastics — from water in just 10 seconds.
While microplastic removal science is promising, it's also important to prevent new particles from entering the environment, and that means reducing our reliance on plastic in our everyday lives. Countries such as England and France are trying to address the microplastic problem through bans on plastic cutlery for most fast food and takeout. California banned plastic produce bags from grocery stores, and India outlawed a selection of single-use plastics.
Do you worry about having toxic forever chemicals in your home?
Majorly
Sometimes
Not really
I don't know enough about them
Click your choice to see results and speak your mind.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Over 6,000 cases of popular ice cream brand recalled over ‘life-threatening' allergen
Over 6,000 cases of popular ice cream brand recalled over ‘life-threatening' allergen

Yahoo

timean hour ago

  • Yahoo

Over 6,000 cases of popular ice cream brand recalled over ‘life-threatening' allergen

A popular brand of ice cream, Breyers, has recalled one of its flavors following customer concerns that there was a mislabeling error. On Tuesday, the United States Food and Drug Administration (FDA) confirmed in a report that 6,668 cases of Breyers Chocolate Truffle Ice Cream were voluntarily recalled by Unilever Manufacturing on June 2 after it was found that the tubs actually contained Rocky Road ice cream. The Chocolate Truffle flavor has an allergen label that reads, 'may contain tree nuts,' while the Rocky Road flavor declares almonds as one of the ingredients. The cause for the recall was determined to be 'undeclared allergens and mislabeled product.' The recall was classified as Class II, which the organization describes as a 'situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.' It was not listed where the affected ice cream was sold, as the FDA's report only states the ice cream was distributed to 'distribution centers and retail locations across the U.S.' In a statement made to People, a representative for Breyers said, 'People with an almond allergy should not consume the product due to risk of serious or life-threatening allergic reaction. The safety and quality of our products are our top priority. For more information, consumers can visit or call 1-800-931-2826.' The recall comes a few weeks after Wells Enterprises, also known as Wells Dairy, issued a voluntary recall of 22 different types of ice cream and frozen yogurt treats. The Iowa-based company initiated the nationwide recall on April 25, citing the possible 'presence of plastic' in more than 17,000 tubs of its products. An enforcement report, published by Wells Enterprises, lists an assortment of products from 103 distribution centers affected by the recall. The items have an expiration date ranging between March and October 2026. The flavor most affected by the issue is its Vanilla Frozen Yogurt, which includes 5,280 recalled tubs. The last two years have also seen an alarming and unexplained rise in recalls. In 2024, approximately 300 food recalls were issued, with those recalls being linked to nearly 1,400 illnesses, a Public Interest Research Group report revealed. Out of the 1,400 illnesses, 487 people became sick enough to require hospitalization, and 19 people died. While those numbers are still low when weighed against the entire U.S. population, they are also double the number of hospitalizations and deaths from foodborne illnesses in 2023.

GE HealthCare and MIM Software release integrated imaging platform
GE HealthCare and MIM Software release integrated imaging platform

Yahoo

timean hour ago

  • Yahoo

GE HealthCare and MIM Software release integrated imaging platform

GE HealthCare has released software combining its own imaging functionalities with tools enabled by a platform developed by MIM Software, to enhance imaging workflows in indications including oncology and cardiology. The integration marks the imaging giant's first combined release with Mim Software's Mim Encore platform since it acquired the company in 2024 for around $290m. Mim Encore is designed to provide features including structured reporting and interpretation tools for PET/CT, SPECT/CT, and multi-modality fusion imaging within a single platform. The platform primarily adds resolution recovery and image-enhancing tools that are tailored for GE HealthCare scanners, Ohio-based Mim Software said. For oncology, the platform in combination with GE HealthCare's systems means that SPECT image processing and analysis can be simplified by the software's ability to perform resolution recovery, attenuation and scatter correction, advanced filtering, and motion correction. Similar functionality through the combination is now possible across cardiology, with Mim's platform also enabling 3D rendering and advanced corrections for GE HealthCare's neurological imaging scanners. Jean-Luc Procaccini, president and CEO for molecular imaging and computed tomography at GE HealthCare commented: 'We are committed to delivering technology that unifies data across systems and organisations, breaking down workflow barriers to help drive better clinical outcomes and elevate the standard of patient care.' According to GE HealthCare, the integration with Mim's platform will allow clinicians and researchers to deliver 'fast, accurate diagnoses, and onboard users quickly' and to realise efficiencies and consistencies in work and communication between clinicians. 'Customers are telling us that this pairing is exactly what users have been looking for. The combined solution enables streamlined, accurate reading of images, supports quantitative analysis out of the box, and helps eliminate manual entries,' said Andrew Nelson, CEO of Mim Software. 'As we continue to evolve our vertically integrated products based on user input, we remain focused on creating a user-friendly, vendor-neutral, future-ready experience designed to scale with advanced molecular imaging needs,' Nelson added. This week at NVIDIA's GTC conference, taking place in Paris, France from 10-12 June, the company announced a new partnership with GE HealthCare that will focus on developing autonomous X-ray technologies and ultrasound applications. "GE HealthCare and MIM Software release integrated imaging platform" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Robotic Pet Company Tombot Secures $6.1M Series A Funding to Support Groundbreaking Health and Senior Care Product Line
Robotic Pet Company Tombot Secures $6.1M Series A Funding to Support Groundbreaking Health and Senior Care Product Line

Business Wire

time4 hours ago

  • Business Wire

Robotic Pet Company Tombot Secures $6.1M Series A Funding to Support Groundbreaking Health and Senior Care Product Line

LOS ANGELES--(BUSINESS WIRE)-- Tombot, the robotics company that earned widespread acclaim at CES earlier this year for its lifelike robotic puppy, Jennie, announced today the successful close—and oversubscription—of its $6.1 million Series A funding round. Tombot's flagship product, Jennie, was designed specifically to treat the Behavioral and Psychological Symptoms of Dementia (BPSD) and other health issues. 'Tombot is entering a high-demand, underserved market at the intersection of mental health and assistive technology,' said Tombot CEO and Co-Founder Tom Stevens. 'Over 300 million seniors around the world with dementia and mild cognitive impairment are unable to care for a live animal at a time when they need the companionship of a pet more than ever. Millions of other individuals suffering from mental health adversities are in a similar predicament.' With artistic design by Jim Henson's Creature Shop, and developed with the guidance of clinical experts, patients, and their families, Jennie provides many of the health benefits associated with live animal ownership, such as reduced stress and loneliness. Jennie will be used in private homes, assisted living and memory care communities, and other settings where live animals are not always safe or practical. Covered with sensors to respond to touch, voice commands, movement, and other sensory inputs, Jennie is rechargeable, fully cleanable, and comes with an optional caregiver app to customize behaviors and ease the burden of caregiving. With participation from both new and existing investors, the funding round was led by Caduceus Capital Partners, a Nashville-based team of veteran healthcare investors with a primary emphasis on accelerating growth of early-stage digital health startups. 'We identified the growing need for robotic companions several years ago and believe the market is now on the brink of exponential expansion,' said Dave Vreeland, senior managing partner, Caduceus Capital Partners. 'By 2030, the U.S. is projected to have 73 million seniors – an aging population that will increasingly face challenges related to loneliness, companionship, and chronic disease management. These issues are rapidly surpassing the capacity of human caregivers alone. Tombot is uniquely positioned to lead this emerging sector and drive widespread adoption of robotic companions." 'This investment will be rocket fuel for Tombot,' said Stevens. 'We are most appreciative of our company's Board of Directors for their ongoing guidance, and are especially grateful to Caduceus for recognizing and supporting Tombot's mission of creating robotic animals that transform the daily lives of individuals, families, and communities facing health adversities.' According to Stevens, this milestone investment will be used to expand Tombot's team, finalize engineering, complete regulatory and safety certifications, and prepare its first robotic pet for customer shipments to its more than 16,000 pre-order and waitlist customers. About Tombot Tombot, Inc., established in 2017, designs realistic robotic companion animals for individuals unable to safely or practically care for a live animal. After Tom Stevens' own mother's progressive dementia necessitated the rehoming of her beloved pet dog for safety reasons, Tom launched Tombot. Tombot's flagship product, Jennie, was designed specifically to treat the Behavioral and Psychological Symptoms of Dementia (BPSD). The Tombot founding team built a prior startup into one of the world's largest legal automation companies and was successfully acquired.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store